View Document Preview and Link Document Date: 2014-05-08 09:44:45 Open Document File Size: 2,10 MB Share Result on Facebook
City Montreal / / Company International Partnership / Merck / ABC / Creative Commons / Achillion Pharmaceuticals / Ardea Biosciences / Hindawi Publishing Corporation / / Country United States / Canada / / / Event FDA Phase / Product Issues / / Facility Antiviral Drug Resistance Mark A. Wainberg Lady Davis Institute / Jewish General Hospital / K65R/L74V/Q151M complex / / IndustryTerm treatment of HIV / HIV therapy / therapy for HIV / / MedicalCondition HIV infection / Introduction Infection / HIV / AIDS / regional epidemics / / MedicalTreatment antiretroviral therapy / highly active antiretroviral therapy / HAART / / Organization McGill University AIDS Centre / Jewish General Hospital / FDA / Federal Trade Commission / Antiviral Drug Resistance Mark A. Wainberg Lady Davis Institute / / Person H. J. Netter / Reverse Transcriptase / Activity Targeted / Mark A. Wainberg / B. Peterson / C. Marchand / M. Clementi / / Position viral RT / mutated viral RT / mutated RT / RT / Major / HIV RT / HIV1 RT / candidate / / Product Efavirenz / zidovudine / THRIVE / S-1360 / Nevirapine / abacavir / lamivudine / adenosine / stavudine / reverse transcriptase inhibitor / DAPY compound / HIV-1 / NH2 / EC50 / DUET-1 / New / PREP microbicide / RDEA806 / / ProvinceOrState Quebec / / PublishedMedium the ECHO / / Technology rational drug design / directed mutagenesis / genotype / recombination / / URL http / SocialTag 
Hindawi Publishing Corporation Scienti�ca Volume 2012, Article ID[removed], 28 pages http://dx.doi.org[removed][removed]Review Article